{"id":267550,"date":"2026-02-04T17:43:08","date_gmt":"2026-02-04T17:43:08","guid":{"rendered":"https:\/\/www.newsbeep.com\/nz\/267550\/"},"modified":"2026-02-04T17:43:08","modified_gmt":"2026-02-04T17:43:08","slug":"novo-nordisk-shares-plunge-on-outlook-warning-as-mounjaro-rival-races-ahead","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/nz\/267550\/","title":{"rendered":"Novo Nordisk shares plunge on outlook warning as Mounjaro rival races ahead"},"content":{"rendered":"\n<p class=\"yf-vbsvxt\">Weight loss drug maker Novo Nordisk has seen shares slump after warning over a sales plunge amid price cuts while a bumper profit haul from its Mounjaro rival Eli Lilly left it trailing behind.<\/p>\n<p class=\"yf-vbsvxt\">Novo Nordisk \u2013 which makes Wegovy and Ozempic \u2013 forecast plunging sales in a surprise after-market announcement on Tuesday, which saw the Danish drugmaker\u2019s shares plummet by nearly a fifth on Wednesday.<\/p>\n<p class=\"yf-vbsvxt\">It said both sales and underlying earnings are expected to fall by between 5% and 13% this year despite the launch of its new Wegovy pill in the US, and chief executive Mike Doustdar cautioned the firm was facing pricing pressures as competition from cheaper rivals intensifies.<\/p>\n<p class=\"yf-vbsvxt\">But its close rival Eli Lilly was enjoying better fortunes as its full-year results on Wednesday showed pre-tax earnings more than doubled to 25.73 billion US dollars (\u00a318.8 billion).<\/p>\n<p class=\"yf-vbsvxt\">Sales of its blockbuster Mounjaro weight loss drug doubled to 23 billion dollars (\u00a316.8 billion) in 2025, having enjoyed a 110% surge in the final three months alone.<\/p>\n<p class=\"yf-vbsvxt\">Eli Lilly\u2019s shares jumped 8% on Wednesday afternoon as it said revenues were set to grow again to between 80 billion and 83 billion dollars (\u00a358.5 billion to \u00a360.6 billion) in 2026, up from 65.2 billion dollars (\u00a347.6 billion) in 2025.<\/p>\n<p class=\"yf-vbsvxt\">Dan Coatsworth, head of markets at AJ Bell, said: \u201cThe weight-loss drugs market has exploded in what many people are calling the biggest opportunity in the healthcare industry for decades.<\/p>\n<p class=\"yf-vbsvxt\">\u201cEven though the market is dominated by just two players, one of them is feeling more pain than gain.<\/p>\n<p class=\"yf-vbsvxt\">\u201cNovo Nordisk has fallen behind with efforts to improve the efficacy of its treatments, leaving Eli Lilly to gobble up market share.<\/p>\n<p class=\"yf-vbsvxt\">\u201cDrug prices are coming down more broadly across the areas in which Novo specialises, and competition is growing.<\/p>\n<p class=\"yf-vbsvxt\">\u201cIt has put the company in a difficult situation, and investors are unhappy, particularly as the healthcare sector more broadly has enjoyed a strong rally since last summer following three years in the doldrums.\u201d<\/p>\n<p class=\"yf-vbsvxt\">Prices have been put under further pressure for the main players after Novo Nordisk and Eli Lilly agreed a plan to appease US President Donald Trump by reducing prices across their ranges and expanding access to them for those on health insurance in America.<\/p>\n<p class=\"yf-vbsvxt\">Novo Nordisk said its sales outlook is \u201cimpacted by lower realised prices, including impacts related to the \u2018Most Favoured Nations\u2019 agreement in the US and the patent expiry of the semaglutide molecule in certain international operations markets, as well as competition\u201d.<\/p>\n<p class=\"yf-vbsvxt\">Mr Doustdar added: \u201cIn 2026, Novo Nordisk will face pricing headwinds in an increasingly competitive market.<\/p>\n","protected":false},"excerpt":{"rendered":"Weight loss drug maker Novo Nordisk has seen shares slump after warning over a sales plunge amid price&hellip;\n","protected":false},"author":2,"featured_media":267551,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[152168,16520,134,527,111,139,14332,69],"class_list":{"0":"post-267550","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-billion-dollars","9":"tag-eli-lilly","10":"tag-health","11":"tag-healthcare","12":"tag-new-zealand","13":"tag-newzealand","14":"tag-novo-nordisk","15":"tag-nz"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/267550","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=267550"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/267550\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/267551"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=267550"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=267550"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=267550"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}